AstraZeneca CEO calls opening IRA drug price offer ‘relatively encouraging’ in first characterization of talks

The first offer to drugmakers under IRA drug price negotiations that began this month is “relatively encouraging,” AstraZeneca CEO Pascal Soriot said Thursday, at least compared with the low expectations the industry had going into the process.

“What we’ve seen is relatively encouraging come back from CMS,” Soriot said during…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks